Background: There are few clinical trials addressing the difference in pleiotropic effects among dipeptidyl peptidase (DPP)-4 inhibitors. We aimed to identify difference in effects on biochemical markers of inflammati...Background: There are few clinical trials addressing the difference in pleiotropic effects among dipeptidyl peptidase (DPP)-4 inhibitors. We aimed to identify difference in effects on biochemical markers of inflammation, oxidative stress, and atherosclerosis between two DPP-4 inhibitors in patients with type 2 diabetes. Methods: We prospectively observed twenty subjects with type 2 diabetes before and after a practical medication change from a treatment with pioglitazone and sitagliptin 50 mg to a combination tablet containing the same dose of pioglitazone and alogliptin 25mg, which was actually identical to switching from sitagliptin to alogliptin. After 3 months, changes from baseline in clinical data and various biochemical markers were evaluated. In particular, body mass index (BMI) and hemoglobin A1c (HbA1c) were additionally followed after 12 months for evaluation of chronic outcomes. Results: Among markers, serum levels of high molecular weight (HMW) adiponectin significantly increased from 6.9 ± 3.6 μg/ml to 8.2 ± 4.0 μg/ml (P = 0.0045). Although no clinical data changed after 3 months, significant improvements in HbA1c and BMI were observed after 12 months. Their rates of changes tended to inversely correlate with the increased percentages of serum HMW adiponectin levels during initial 3 months, but they did not reach statistical significance. Conclusions: In spite of pretreatment with pioglitazone, additional increase in serum HMW adiponectin levels was demonstrated after switching from sitagliptin to alogliptin. Given multiple favorable roles of adiponectin in metabolic and cardiovascular states, alogliptin, at least when combined with pioglitazone, would be beneficial in treatment of type 2 diabetes.展开更多
Adiponectin is an adipocyte-secreted hormone and regulates the metabolism of lipid and glucose. We examined the influence of adiponectin G276T gene polymorphism on changes in total or high molecular weight adiponectin...Adiponectin is an adipocyte-secreted hormone and regulates the metabolism of lipid and glucose. We examined the influence of adiponectin G276T gene polymorphism on changes in total or high molecular weight adiponectin levels by exercise training. A randomized parallel-design study (n = 53;40 women and 13 men;age range, 32 - 65 years) was conducted. Participants were randomly assigned to the exercise (n = 26) or control (n = 27) group and received exercise training for 70 min 2 times per week for 12 weeks and exercise advice at the baseline, respectively. Blood sample were obtained before and after the intervention. The primary outcomes were changes in total adiponectin and high molecular weight adiponectin levels. At the baseline, the participants with and without 276G allele did not differ with the total and high molecular weight adiponectin levels in the entire study population. No significant difference in the change in the total and high molecular weight adiponectin levels between the subjects with the G276G genotype and 276T allele carriers were found. This study provides evidence that the G276T polymorphism of the adiponectin gene is not associated with the magnitude of the effect of twice-weekly exercise training on the total and high molecular weight adiponectin levels.展开更多
目的初步探讨代谢正常肥胖(MHO)人群中脂联素(APN)分子构成的变化及临床意义,分析MHO人群代谢正常的原因,并探讨其与MHO的相关性。方法根据纳入标准选取成年人161例,分为MHO组(n=52)、肥胖伴代谢综合征(MS)组(n=52)、正常对照组(n=57)...目的初步探讨代谢正常肥胖(MHO)人群中脂联素(APN)分子构成的变化及临床意义,分析MHO人群代谢正常的原因,并探讨其与MHO的相关性。方法根据纳入标准选取成年人161例,分为MHO组(n=52)、肥胖伴代谢综合征(MS)组(n=52)、正常对照组(n=57)。采用酶联免疫吸附法(ELISA)测定患者血清总APN、高分子量脂联素(HMW-adp)浓度,并分析其分子构成在MHO人群中的变化及相关临床意义。结果 (1)与正常对照组相比,肥胖伴MS组及MHO组血清总APN、HMW-adp均明显降低(P<0.01);(2)MHO组总APN、HMW-adp较肥胖伴MS组明显升高(P<0.01);(3)MHO组HMW-adp/总APN(H/A)较肥胖伴MS组及正常对照组均升高(P<0.05);(4)多元逐步回归分析显示体质指数(BMI)、腰围、餐后2 h血糖(2 hP BG)是总APN的重要危险因素,腰围、2 hP BG是HMW-adp的负性预测因子,而高密度脂蛋白胆固醇(HDL-C)是其唯一的阳性预测因子,而H/A的主要影响因素却是BMI、腰围、HDL-C。结论 APN分子构成在MHO人群中呈高水平状态,该人群代谢之所以正常可能与这两种因子的保护作用有关,尤其HMW-adp。由此可以认为血清总APN、HMW-adp的检测可作为定量检测MHO人群及其转归以及判断预后的指标。展开更多
目的:观察原发性高血压患者血清高分子质量(high molecular weight,HMW)脂联素水平,探讨其与血压、肥胖、糖脂代谢、胰岛素抵抗及超敏C反应蛋白(hs-CRP)的关系。方法:纳入76例研究对象,以有无原发性高血压分为对照组和高血压组(各38例)...目的:观察原发性高血压患者血清高分子质量(high molecular weight,HMW)脂联素水平,探讨其与血压、肥胖、糖脂代谢、胰岛素抵抗及超敏C反应蛋白(hs-CRP)的关系。方法:纳入76例研究对象,以有无原发性高血压分为对照组和高血压组(各38例)。所有研究对象均行口服75g葡萄糖耐量试验(OGTT),检测空腹血糖、餐后2 h血糖(2 h PG)、空腹胰岛素(FINS)、餐后2 h胰岛素(2 h INS)及血脂水平,并以稳态模型评估胰岛素抵抗指数(HOMA-IR)。采用化学发光法检测血清hs-CRP水平,酶免法检测HMW脂联素水平。结果:高血压组血清HMW脂联素质量浓度为0.82(0.46~1.46)ng/L,明显低于对照组[2.53(1.70~5.75)ng/L,P<0.01]。相关分析显示血清HMW脂联素与收缩压、舒张压、平均动脉压(MAP)、体质量指数(BMI)、腰臀比、三酰甘油、空腹血糖、2 h PG、HOMA-IR、hs-CRP呈负相关,与高密度脂蛋白胆固醇(HDL-C)呈显著正相关。多元逐步回归分析提示收缩压、三酰甘油是血清HMW脂联素水平的独立影响因素(P<0.05)。二分类Logistic回归分析表明,HMW脂联素是高血压的保护因素(P<0.01)。结论:原发性高血压人群血清HMW脂联素水平明显降低,且与血压、肥胖、糖脂代谢、胰岛素抵抗及hs-CRP密切相关,提示低HMW脂联素血症可能参与了原发性高血压的发生发展。展开更多
为评价血液指标对冠状动脉狭窄早期诊断及分级的价值,选择冠状动脉狭窄患者125例(观察组)及同期健康体检者125例(对照组)进行了研究.检测了两组小而密低密度脂蛋白(small and dense low-density lipoprotein,sd-LDL)、血浆总脂联素、高...为评价血液指标对冠状动脉狭窄早期诊断及分级的价值,选择冠状动脉狭窄患者125例(观察组)及同期健康体检者125例(对照组)进行了研究.检测了两组小而密低密度脂蛋白(small and dense low-density lipoprotein,sd-LDL)、血浆总脂联素、高分子脂联素的水平.比较两组各血液指标,采用Gensini评分对冠状动脉狭窄进行分级,分析了不同分级患者各指标.结果表明:观察组血浆总脂联素、高分子脂联素水平均显著低于对照组(P<0.05),观察组sd-LDL高于对照组(P<0.05).血浆总脂联素、高分子脂联素均为轻度病变组>中度病变者>重度病变组,sd-LDL为轻度病变组<中度病变者<重度病变组(P<0.05).冠状动脉狭窄患者血浆总脂联素、高分子脂联素水平与总Gensini评分均呈显著的负相关关系,sd-LDL与总Gensini评分呈正相关关系(P<0.05).ROC分析结果显示:sd-LDL、血浆总脂联素、高分子脂联素对冠状动脉狭窄早期诊断的截断值分别为0.545、12.235、5.445 mg·L^(-1);曲线下面积(AUC)分别为0.724、0.751、0.759.三者联合诊断的AUC为0.931,其诊断效能高于各指标单独(P<0.05).说明sd-LDL、血浆总脂联素、高分子脂联素与冠状动脉狭窄严重程度分级相关,且上述指标可用于冠状动脉狭窄的早期诊断.展开更多
文摘Background: There are few clinical trials addressing the difference in pleiotropic effects among dipeptidyl peptidase (DPP)-4 inhibitors. We aimed to identify difference in effects on biochemical markers of inflammation, oxidative stress, and atherosclerosis between two DPP-4 inhibitors in patients with type 2 diabetes. Methods: We prospectively observed twenty subjects with type 2 diabetes before and after a practical medication change from a treatment with pioglitazone and sitagliptin 50 mg to a combination tablet containing the same dose of pioglitazone and alogliptin 25mg, which was actually identical to switching from sitagliptin to alogliptin. After 3 months, changes from baseline in clinical data and various biochemical markers were evaluated. In particular, body mass index (BMI) and hemoglobin A1c (HbA1c) were additionally followed after 12 months for evaluation of chronic outcomes. Results: Among markers, serum levels of high molecular weight (HMW) adiponectin significantly increased from 6.9 ± 3.6 μg/ml to 8.2 ± 4.0 μg/ml (P = 0.0045). Although no clinical data changed after 3 months, significant improvements in HbA1c and BMI were observed after 12 months. Their rates of changes tended to inversely correlate with the increased percentages of serum HMW adiponectin levels during initial 3 months, but they did not reach statistical significance. Conclusions: In spite of pretreatment with pioglitazone, additional increase in serum HMW adiponectin levels was demonstrated after switching from sitagliptin to alogliptin. Given multiple favorable roles of adiponectin in metabolic and cardiovascular states, alogliptin, at least when combined with pioglitazone, would be beneficial in treatment of type 2 diabetes.
文摘Adiponectin is an adipocyte-secreted hormone and regulates the metabolism of lipid and glucose. We examined the influence of adiponectin G276T gene polymorphism on changes in total or high molecular weight adiponectin levels by exercise training. A randomized parallel-design study (n = 53;40 women and 13 men;age range, 32 - 65 years) was conducted. Participants were randomly assigned to the exercise (n = 26) or control (n = 27) group and received exercise training for 70 min 2 times per week for 12 weeks and exercise advice at the baseline, respectively. Blood sample were obtained before and after the intervention. The primary outcomes were changes in total adiponectin and high molecular weight adiponectin levels. At the baseline, the participants with and without 276G allele did not differ with the total and high molecular weight adiponectin levels in the entire study population. No significant difference in the change in the total and high molecular weight adiponectin levels between the subjects with the G276G genotype and 276T allele carriers were found. This study provides evidence that the G276T polymorphism of the adiponectin gene is not associated with the magnitude of the effect of twice-weekly exercise training on the total and high molecular weight adiponectin levels.
文摘目的初步探讨代谢正常肥胖(MHO)人群中脂联素(APN)分子构成的变化及临床意义,分析MHO人群代谢正常的原因,并探讨其与MHO的相关性。方法根据纳入标准选取成年人161例,分为MHO组(n=52)、肥胖伴代谢综合征(MS)组(n=52)、正常对照组(n=57)。采用酶联免疫吸附法(ELISA)测定患者血清总APN、高分子量脂联素(HMW-adp)浓度,并分析其分子构成在MHO人群中的变化及相关临床意义。结果 (1)与正常对照组相比,肥胖伴MS组及MHO组血清总APN、HMW-adp均明显降低(P<0.01);(2)MHO组总APN、HMW-adp较肥胖伴MS组明显升高(P<0.01);(3)MHO组HMW-adp/总APN(H/A)较肥胖伴MS组及正常对照组均升高(P<0.05);(4)多元逐步回归分析显示体质指数(BMI)、腰围、餐后2 h血糖(2 hP BG)是总APN的重要危险因素,腰围、2 hP BG是HMW-adp的负性预测因子,而高密度脂蛋白胆固醇(HDL-C)是其唯一的阳性预测因子,而H/A的主要影响因素却是BMI、腰围、HDL-C。结论 APN分子构成在MHO人群中呈高水平状态,该人群代谢之所以正常可能与这两种因子的保护作用有关,尤其HMW-adp。由此可以认为血清总APN、HMW-adp的检测可作为定量检测MHO人群及其转归以及判断预后的指标。
文摘目的:观察原发性高血压患者血清高分子质量(high molecular weight,HMW)脂联素水平,探讨其与血压、肥胖、糖脂代谢、胰岛素抵抗及超敏C反应蛋白(hs-CRP)的关系。方法:纳入76例研究对象,以有无原发性高血压分为对照组和高血压组(各38例)。所有研究对象均行口服75g葡萄糖耐量试验(OGTT),检测空腹血糖、餐后2 h血糖(2 h PG)、空腹胰岛素(FINS)、餐后2 h胰岛素(2 h INS)及血脂水平,并以稳态模型评估胰岛素抵抗指数(HOMA-IR)。采用化学发光法检测血清hs-CRP水平,酶免法检测HMW脂联素水平。结果:高血压组血清HMW脂联素质量浓度为0.82(0.46~1.46)ng/L,明显低于对照组[2.53(1.70~5.75)ng/L,P<0.01]。相关分析显示血清HMW脂联素与收缩压、舒张压、平均动脉压(MAP)、体质量指数(BMI)、腰臀比、三酰甘油、空腹血糖、2 h PG、HOMA-IR、hs-CRP呈负相关,与高密度脂蛋白胆固醇(HDL-C)呈显著正相关。多元逐步回归分析提示收缩压、三酰甘油是血清HMW脂联素水平的独立影响因素(P<0.05)。二分类Logistic回归分析表明,HMW脂联素是高血压的保护因素(P<0.01)。结论:原发性高血压人群血清HMW脂联素水平明显降低,且与血压、肥胖、糖脂代谢、胰岛素抵抗及hs-CRP密切相关,提示低HMW脂联素血症可能参与了原发性高血压的发生发展。
